Tigecycline Production Cost Reports

The report provides a detailed analysis essential for establishing a Tigecycline production plant. It encompasses all critical aspects necessary for Tigecycline production, including the cost of Tigecycline production, Tigecycline plant cost, Tigecycline production costs, and the overall Tigecycline production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Tigecycline production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Tigecycline is an intravenous antibiotic that belongs to the glycylcycline family. It works by binding to the 30S ribosomal subunit of bacteria to prevent protein synthesis essential for their growth and survival. It has bactericidal and bacteriostatic activity against challenging pathogens like Gram-positive organisms like MRSA and VRE, Gram-negative bacteria like extended-spectrum beta-lactamase-producing.

It is utilised in complicated skin and skin structure infections caused by susceptible strains of Escherichia coli, Enterococcus faecalis, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus anginosus group, etc. It is also used in complicated intra-abdominal infections and community-acquired bacterial pneumonia from Streptococcus pneumoniae (penicillin-susceptible isolates), Haemophilus influenzae, or Legionella pneumophila.

The market for Tigecycline is driven by a rise in antibiotic resistance, particularly multidrug-resistant bacterial infections. Its utilisation in complicated skin and soft tissue, intra-abdominal, and hospital-acquired infections, along with rising healthcare spending, contributes to its market growth. The expanding geriatric vulnerability to infections, strong demand in hospitals as the dominant segment, and advancements in generics for cost accessibility fuel its market. The industrial Tigecycline procurement is affected by GMP-certified API suppliers with regulatory compliance in key markets like the US, EU, Japan, and Korea.  Other factors, like impurity profiles and stability data, with Asia leading production for cost efficiencies while buyers focus on audited chains, affect its market dynamics.

Raw Material for Tigecycline Production

According to the Tigecycline production plant project report, the key raw materials used in the production of Tigecycline include 9-Chloroacetaminominocycline, tert-butylamine, sodium iodide, and N, N-dimethylacetamide.

Production Process of Tigecycline

The extensive Tigecycline production cost report consists of the following major industrial production process:

1. From 9-Chloroacetaminominocycline: The Tigecycline production involves substituting the 9-chloroacetyl group on 9-chloroacetaminominocycline. The process starts by charging N, N-dimethylacetamide and 9-chloroacetaminominocycline in a reactor. This is followed by adding tert-butylamine and sodium iodide, which displaces the chloro group and forms tigecycline. The product is separated and purified to get pure Tigecycline as the final product.

Tigecycline is a glycylcycline antibiotic with a molecular formula of C29H39N5O8 and a molecular weight of 585.65 g/mol. It's free base forms an orange, hygroscopic powder or cake that has a melting point at 180-183 degree Celsius, with a density of about 1.45 g/cm³. It is freely soluble in water, soluble in DMSO, slightly soluble in anhydrous ethanol, and insoluble in heptane. The lyophilised formulation contains lactose or maltose excipients. It has a logP (octanol/water) value of 0.66-2.7, pKa of around 4.5, and polar surface area of 205.76 Ų. Its stability requires storage at -20 degree Celsius under an inert atmosphere in the dark, with decomposition risks and plasma protein binding of 68%.